RxDoctor Payments Data

Christopher Granger, MD

Family Medicine · Dunlap, TNNPI 1861472110

Payments from drug & device makers

$13,457in general payments, 2019–2025

Across 54 payments — averaging $249.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche Diagnostics International Ltd$11K
  • Medtronic$2K
  • Irhythm Technologies, Inc.$227
  • Novo Nordisk$213
  • AbbVie$94
  • AstraZeneca$55
  • plus $296 from 13 others

What the payments were for

  • Speaking & faculty fees$2,41518%
  • Travel & lodging$9,19668%
  • Food & beverage$1,81713%
  • Education$300%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,457 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$500,500
Medicare patients
778
Services billed
7,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide237$252,712
EliquisApixaban429$233,645
IngrezzaValbenazine Tosylate63$233,566
JardianceEmpagliflozin206$158,273
TrulicityDulaglutide101$103,090
MounjaroTirzepatide60$72,297
JanuviaSitagliptin Phosphate115$59,888
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$49,032
XareltoRivaroxaban56$38,147
LinzessLinaclotide32$24,011
FarxigaDapagliflozin Propanediol24$23,075
RexultiBrexpiprazole25$22,419
Pantoprazole Sodium835$22,358
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$21,983
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$17,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$213$252,712237 claims
Lilly USA, LLCTrulicity, Mounjaro$43$175,387161 claims
Boehringer IngelheimJardiance, Spiriva Respimat$27$164,814219 claims
AbbVieLinzess$94$24,01132 claims
AstraZenecaFarxiga$55$23,07524 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17$22,41925 claims
Astellas Pharma US IncMyrbetriq$14$15,60128 claims
NovartisEntresto$19$11,33936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Dunlap

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →